手术治疗复发性转移性子宫平滑肌肉瘤患者的预后因素和生存率。

IF 1.6 Q4 ONCOLOGY
International Journal of Surgical Oncology Pub Date : 2014-01-01 Epub Date: 2014-06-22 DOI:10.1155/2014/919323
Han L T Hoang, Kelsey Ensor, Gerald Rosen, H Leon Pachter, Joseph S Raccuia
{"title":"手术治疗复发性转移性子宫平滑肌肉瘤患者的预后因素和生存率。","authors":"Han L T Hoang,&nbsp;Kelsey Ensor,&nbsp;Gerald Rosen,&nbsp;H Leon Pachter,&nbsp;Joseph S Raccuia","doi":"10.1155/2014/919323","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Uterine leiomyosarcoma (LMS) is a rare diagnosis, which is seldom cured when it recurs with metastatic disease. We evaluated patients who present with first time recurrence treated surgically to determine prognostic factors associated with long-term survival.</p><p><strong>Methods: </strong>Over a 16-year period, 41 patients were operated on for recurrent uterine sarcoma. Data examined included patient age, date of initial diagnosis, tumor histology, grade at the initial diagnosis, cytopathology changes in tumor activity from the initial diagnosis, residual tumor after all operations, use of adjuvant therapy, dates and sites of all recurrences, and disease status at last followup.</p><p><strong>Results: </strong>24 patients were operated for first recurrence of metastatic uterine LMS. Complete tumor resection with histologic negative margins was achieved in 16 (67%) patients. Overall survival was significantly affected by the FIGO stage at the time of the initial diagnosis, the ability to obtain complete tumor resection at the time of surgery for first time recurrent disease, single tumor recurrence, and recurrence greater than 12 months from the time of the initial diagnosis. Median disease-free survival was 14 months and overall survival was 27 months.</p><p><strong>Conclusion: </strong>Our findings suggest that stage 1 at the time of initial diagnosis, recurrence greater than 12 months, isolated tumor recurrence, and the ability to remove ability to perform complete tumor resection at the time of the first recurrence can afford improved survival in selected patientsat the time of the first recurrence can afford improved survival in selected patients.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/919323","citationCount":"13","resultStr":"{\"title\":\"Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma.\",\"authors\":\"Han L T Hoang,&nbsp;Kelsey Ensor,&nbsp;Gerald Rosen,&nbsp;H Leon Pachter,&nbsp;Joseph S Raccuia\",\"doi\":\"10.1155/2014/919323\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Uterine leiomyosarcoma (LMS) is a rare diagnosis, which is seldom cured when it recurs with metastatic disease. We evaluated patients who present with first time recurrence treated surgically to determine prognostic factors associated with long-term survival.</p><p><strong>Methods: </strong>Over a 16-year period, 41 patients were operated on for recurrent uterine sarcoma. Data examined included patient age, date of initial diagnosis, tumor histology, grade at the initial diagnosis, cytopathology changes in tumor activity from the initial diagnosis, residual tumor after all operations, use of adjuvant therapy, dates and sites of all recurrences, and disease status at last followup.</p><p><strong>Results: </strong>24 patients were operated for first recurrence of metastatic uterine LMS. Complete tumor resection with histologic negative margins was achieved in 16 (67%) patients. Overall survival was significantly affected by the FIGO stage at the time of the initial diagnosis, the ability to obtain complete tumor resection at the time of surgery for first time recurrent disease, single tumor recurrence, and recurrence greater than 12 months from the time of the initial diagnosis. Median disease-free survival was 14 months and overall survival was 27 months.</p><p><strong>Conclusion: </strong>Our findings suggest that stage 1 at the time of initial diagnosis, recurrence greater than 12 months, isolated tumor recurrence, and the ability to remove ability to perform complete tumor resection at the time of the first recurrence can afford improved survival in selected patientsat the time of the first recurrence can afford improved survival in selected patients.</p>\",\"PeriodicalId\":45960,\"journal\":{\"name\":\"International Journal of Surgical Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2014-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2014/919323\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Surgical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2014/919323\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2014/6/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2014/919323","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/6/22 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 13

摘要

背景:子宫平滑肌肉瘤(LMS)是一种罕见的诊断,当它与转移性疾病复发时很少治愈。我们对首次手术复发的患者进行评估,以确定与长期生存相关的预后因素。方法:16年来对41例复发性子宫肉瘤进行手术治疗。检查的资料包括患者的年龄、初诊日期、肿瘤组织学、初诊时的分级、初诊时肿瘤活动性的细胞病理学变化、所有手术后的残留肿瘤、辅助治疗的使用、所有复发的日期和部位以及最后随访时的疾病状态。结果:24例转移性子宫LMS首次复发均行手术治疗。16例(67%)患者实现了组织学边缘阴性的肿瘤完全切除。初诊时的FIGO分期、首次复发疾病手术时获得肿瘤完全切除的能力、单次肿瘤复发以及自初诊时复发大于12个月对总生存率有显著影响。中位无病生存期为14个月,总生存期为27个月。结论:我们的研究结果表明,在初次诊断时处于1期,复发大于12个月,孤立肿瘤复发,以及在第一次复发时进行完全肿瘤切除的能力可以改善选定患者的生存,第一次复发时可以改善选定患者的生存。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma.

Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma.

Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma.

Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma.

Background: Uterine leiomyosarcoma (LMS) is a rare diagnosis, which is seldom cured when it recurs with metastatic disease. We evaluated patients who present with first time recurrence treated surgically to determine prognostic factors associated with long-term survival.

Methods: Over a 16-year period, 41 patients were operated on for recurrent uterine sarcoma. Data examined included patient age, date of initial diagnosis, tumor histology, grade at the initial diagnosis, cytopathology changes in tumor activity from the initial diagnosis, residual tumor after all operations, use of adjuvant therapy, dates and sites of all recurrences, and disease status at last followup.

Results: 24 patients were operated for first recurrence of metastatic uterine LMS. Complete tumor resection with histologic negative margins was achieved in 16 (67%) patients. Overall survival was significantly affected by the FIGO stage at the time of the initial diagnosis, the ability to obtain complete tumor resection at the time of surgery for first time recurrent disease, single tumor recurrence, and recurrence greater than 12 months from the time of the initial diagnosis. Median disease-free survival was 14 months and overall survival was 27 months.

Conclusion: Our findings suggest that stage 1 at the time of initial diagnosis, recurrence greater than 12 months, isolated tumor recurrence, and the ability to remove ability to perform complete tumor resection at the time of the first recurrence can afford improved survival in selected patientsat the time of the first recurrence can afford improved survival in selected patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.70
自引率
0.00%
发文量
5
审稿时长
20 weeks
期刊介绍: International Journal of Surgical Oncology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of surgical oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信